Ustekinumab for the treatment of Crohn’s disease

References

• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–250.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61:241–247.
   PubMed Web of Science ®Google Scholar
• van Der Valk ME, Mangen MJ, Leenders M, et al. Risk factors of work disability in patients with inflammatory bowel disease – a Dutch nationwide web-based survey: work disability in inflammatory bowel disease. J Crohns Colitis. 2014;8:590–597.
   PubMed Web of Science ®Google Scholar
• Huppertz-Hauss G, Høivik ML, Langholz E, et al. Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis. Inflamm Bowel Dis. 2015;21:337–344.
   PubMed Web of Science ®Google Scholar
• Gordon JP, McEwan PC, Maguire A, et al. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015;27:804–812.
   PubMed Web of Science ®Google Scholar
• Allen PB, Peyrin-Biroulet L. Immunomodulators for the treatment of Crohn’s disease in adults: optimal use and prospects for future drug treatments. Expert Rev Clin Immunol. 2016;12:741–749.
   PubMedGoogle Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Liberato NL. Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Rev Pharmacoecon Outcomes Res. 2014;14:815–824.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–667.
   PubMed Web of Science ®Google Scholar
• Leombruno JP, Nguyen GC, Grootendorst P, et al. Hospitalization and surgical rates in patients with Crohn’s disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf. 2011;20:838–848.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58:492–500.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–1139.
   PubMed Web of Science ®Google Scholar
• Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567–577.
   PubMed Web of Science ®Google Scholar
• Rahier J-F, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048–1055.
   PubMed Web of Science ®Google Scholar
• Puig L, Morales-Múnera CE, López-Ferrer A, et al. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology. 2012;225:14–17.
   PubMed Web of Science ®Google Scholar
• Smith MA, Mohammad RA. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases. Ann Pharmacother. 2014;48:1629–1635.
   PubMed Web of Science ®Google Scholar
• Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016 Jul 1. [Epub ahead of print].
   PubMedGoogle Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–1880.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–368.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. J Neuroimmunol. 2013;264:123–126.
   Google Scholar
• Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013;264:123–126.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618–627. e3.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12:1485–1493. e2.
   PubMed Web of Science ®Google Scholar
• A open-label study of CP-690,550 as long-term therapy (48 weeks) in subjects with Crohn’s disease. [Cited 2016 May 18]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01470599
   Google Scholar
• Monteleone G, Fantini MC, Onali S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease. Mol Ther. 2012;20:870–876.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372:1104–1113.
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of subjects with active Crohn’s disease. [Cited 2016 May 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02596893
   Google Scholar
• Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut. 2009;58:1152–1167.
   PubMed Web of Science ®Google Scholar
• Sands BE, Chen J, Penney M, et al. Initial evaluation of MEDI2070 (specific anti-IL-23 antibody) in patients with active Crohn’s disease who have failed anti-TNF antibody therapy: a randomized, double-blind placebo-controlled phase 2A induction study. Gastroenterology. 2015;148(4 Supp1):S163–S164.
   Google Scholar
• Stelara product characteristics. Janssen Inc. 2015 [cited 2016 Mar 30]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf
   Google Scholar
• Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy. 2013;5:803–815.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558.
   PubMed Web of Science ®Google Scholar
• Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–1316.
   PubMed Web of Science ®Google Scholar
• Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203:2473–2483.
   PubMed Web of Science ®Google Scholar
• Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719–729.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–1141.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao -L-L, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–1528.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Gasink C, Blank M, et al. O-001 A multicenter, double-blind, placebo-controlled phase3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohnʼs disease refractory to anti-TFNα. Inflamm Bowel Dis. 2016;22(Suppl 1):S1.
   Google Scholar
• Feagan B. A Multicenter, randomized, double-blind, placebo-controlled phase 3 study of ustekinumab, a human monoclonal antibody to IL-12/23P40, in patients with moderately to severely-active Crohn’s disease who are naive or not refractory to anti-TNFα: results from the UNITI-2 study. Presented at ACG Meeting; 2015; Honolulu, HI.
   Google Scholar
• A study to evaluate the safety and efficacy of ustekinumab maintenance therapy in patients with moderately to severely active Crohn’s disease (IM-UNITI). Available from: https://clinicaltrials.gov/ct2/show/NCT01369355
   Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242–250.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experience. J Crohns Colitis. 2014;8:1516–1522.
   PubMed Web of Science ®Google Scholar
• Harris KA, Horst S, Gadani A, et al. Patients with refractory Crohn’s disease successfully treated with ustekinumab. Inflamm Bowel Dis. 2016;22:397–401.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Feagan BG, Gasink C, et al. 768 A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate – severe Crohn’s disease patients: results from IM-UNITI. Gastroenterology. 2016;150:S157–S158.
   Google Scholar
• Press release: Janssen submits applications seeking approval of Stelara in United States and European Union for Crohn’s disease. [cited 2016 May 14]. Available from: https://www.jnj.com/news/all/Janssen-Submits-Applications-Seeking-Approval-Of-STELARA-In-United-States-And-European-Union-For-Crohns-Disease
   Google Scholar